Veracyte

NMQ:VCYT · US92337F1075

BiotechnologyMedium

360

Value47

Profit price17

EV / EBIT29

Price / Owner Earnings5

Cash yield88

Sales & asset price54

Price/Sales64

EV / Gross Profit52

Price/Book47

Quality70

Returns on capital84

Return on Capital81

Cash Return on Capital86

Return on Equity84

Profit margins66

EBIT Margin76

Gross Profitability56

Cash backing71

Accruals56

Owner Earnings Margin85

Growth55

Sales growth51

Profit growth67

Profit Growth96

Long-Term EPS Growth38

Reinvestment64

Price momentum63

Safety64

Debt load68

Debt serviceability96

Refinancing91

Debt Payback100

Liquidity100

Sentiment44

Analyst ratings22

Expectations trend12

Opinion Changes16

Price Target Upside8

Market mood71

Value Creation14/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Veracyte generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeNASDAQGM

Founded2006

Employees626

Websiteveracyte.com

ISINUS92337F1075

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

UrologyGeneticsArtificial IntelligenceEndocrinologyHealth DiagnosticsOncologyPulmonologyBiotechnologyHealth Care

Description

Veracyte, Inc. (the company) operates as a global diagnostics organization that empowers clinicians with high-value insights needed to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. The company's high-performi…

Analysis

Quality compounder

Veracyte, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 38.2×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Veracyte with its peers

Guardant Health

NSQ:GH

CountryUSA

IndustryHealth Care Providers & Services

SizeLarge

Full Stock Analysis →

Anixa Biosciences

NAQ:ANIX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Janux Therapeutics

NMQ:JANX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Celcuity

NAQ:CELC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Myriad Genetics

NSQ:MYGN

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Oric Pharmaceuticals

NSQ:ORIC

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →